5441842025-10-012025-12-315441842025-12-315441842025-04-012025-12-315441842025-10-012025-12-31in-capmkt:OtherExpenses1Member5441842025-04-012025-12-31in-capmkt:OtherExpenses1Member5441842025-10-012025-12-31in-capmkt:ReportableSegments1Member5441842025-10-012025-12-31in-capmkt:ReportableSegments2Member5441842025-10-012025-12-31in-capmkt:ReportableSegments3Member5441842025-04-012025-12-31in-capmkt:ReportableSegments1Member5441842025-04-012025-12-31in-capmkt:ReportableSegments2Member5441842025-04-012025-12-31in-capmkt:ReportableSegments3Member5441842025-10-012025-12-31in-capmkt:ReportableSegments1Member5441842025-10-012025-12-31in-capmkt:ReportableSegments2Member5441842025-10-012025-12-31in-capmkt:ReportableSegments3Member5441842025-04-012025-12-31in-capmkt:ReportableSegments1Member5441842025-04-012025-12-31in-capmkt:ReportableSegments2Member5441842025-04-012025-12-31in-capmkt:ReportableSegments3Member5441842025-10-012025-12-31in-capmkt:ReportableSegments1Member5441842025-12-31in-capmkt:ReportableSegments1Member5441842025-10-012025-12-31in-capmkt:ReportableSegments2Member5441842025-12-31in-capmkt:ReportableSegments2Member5441842025-10-012025-12-31in-capmkt:ReportableSegments3Member5441842025-12-31in-capmkt:ReportableSegments3Member5441842025-10-012025-12-31in-capmkt:ReportableSegments1Member5441842025-12-31in-capmkt:ReportableSegments1Member5441842025-10-012025-12-31in-capmkt:ReportableSegments2Member5441842025-12-31in-capmkt:ReportableSegments2Member5441842025-10-012025-12-31in-capmkt:ReportableSegments3Member5441842025-12-31in-capmkt:ReportableSegments3Member5441842025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15441842025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15441842025-10-012025-12-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares544184BOROSCINOTLISTEDINE02L001032BOROSIL SCIENTIFIC LIMITEDMain BoardEquity2025-04-012026-03-312026-02-112026-02-04INRLakhsQuarterlyThird quarterMulti segment2026-02-1114:00:002026-02-1115:45:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated121297600024155000123713100041197700038404000-145150002156970002554000478580003895470001091522000145609000-1915100012645800039489000-6000394830000869750000000869750002470008722200086753000222000870000002220008894700010.980.98000.980.98000Notes on Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2025: <BR> <BR> 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11th February, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the above results. <BR> <BR> 2. Pursuant to exercise of the options issued under “Borosil Scientific Limited - Special Purpose Employee Stock Option Plan 2023”, the Company has made allotment of Nil Equity Shares and 13,747 Equity Shares, respectively of the face value of Re. 1/- each for the quarter and nine months ended 31st December, 2025, which has resulted into increase of paid up Equity Share Capital by Nil and Rs. 0.14 lakhs, respectively and Securities Premium by Nil and Rs. 15.14 lakhs, respectively. <BR> <BR> 3. As informed earlier, the Company had introduced a Voluntary Retirement Scheme (VRS) for the eligible workers at its plant situated at Village Ambad, Nashik, Maharashtra . During the first quarter, the Company entered into a Memorandum of Settlement, with the Bhartiya Kamgar Sena (BKS), outlining the terms of final settlement under VRS. BKS is a trade union registered under Trade Union’s Act, 1926, representing the said eligible workers. The above settlement resulted total expenditure of Rs. 661.31 lakhs (including professional fees related to the above) for nine months ended 31st December, 2025 and shown as an exceptional item in the above results. <BR> <BR> 4. Effective from 21st November, 2025, the Government of India has consolidated 29 existing labour legislations into a united framework comprising four Labour Codes. On the basis of best available information, the Company has assessed the one time incremental impact of Rs. 191.51 lakhs for the quarter and nine months ended 31st December, 2025 and disclosed as an exceptional item in the above results. The Company continues to monitor the finalisation of Central / State Government Rules and clarifications in relation to newly introduced Labour Code and would provide appropriate accounting effect on the basis of new developments, if required. <BR> <BR> 5. The figures for the corresponding previous period/year have been rearranged/ regrouped, wherever necessary, to make them comparable. <BR> <BR> <BR> For Borosil Scientific Limited <BR> <BR> <BR> <BR> <BR> Place: Mumbai Vinayak Patankar <BR> Date : 11th February, 2026 Whole-time Director & CEO <BR> (DIN 07534225) <BR> 2025-04-012025-12-31UnauditedConsolidated3241728000748320003316560000113973400082962000-54574000622673000865400014476600011500770003094292000222268000-8528200013698600070327000-669400063633000073353000000073353000-880007326500074037000-68400073955000-6900008894700010.830.83000.830.83000Other Expences389547000Other Expences1150077000Scientific – Laboratory Glass & equipment and Process System872635000Glassware328905000Others11436000Scientific – Laboratory Glass & equipment and Process System2213221000Glassware990373000Others38134000121297600032417280000012129760003241728000Scientific – Laboratory Glass & equipment and Process System205237000Glassware-29787000Others7150000Scientific – Laboratory Glass & equipment and Process System413805000Glassware-94047000Others157190001826000003354770002554000865400053588000189837000126458000136986000Scientific – Laboratory Glass & equipment and Process System2045913000Glassware1072489000Others29882000314828400019614060005109690000Scientific – Laboratory Glass & equipment and Process System568187000Glassware180786000Others2828000751801000219483000971284000Note : <BR> <BR> As per Indian Accounting Standard 108 on ‘Operating Segment’ (Ind-AS 108), the Group has reported "Segment information", as described below: <BR> <BR> Scientific – Laboratory Glass & equipment and Process System:- Comprising of items used in laboratories, production floor and research and development <BR> Glassware:- pharmaceutical primary packaging and domestic glassware items <BR> Others :- Comprising of Filter Paper etc. <BR> Unallocated:- Consists of income, expenses, assets and liabilities which can not be directly identified to any of the above segments.Re-measurement gains / (losses) on defined benefit plans331000331000Re-measurement gains / (losses) on defined benefit plans-117000-11700084000-2900000247000-88000UnauditedtrueM/s. Chaturvedi & Shah LLP, Chartered Accountantstrue2026-06-30